IGF2BP1 Protein

Migration, Crosslink

📖

IGF2BP1 Protein

active

wiki page Created: 2026-04-02T07:19:10 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-igf2bp1-protein

📖 Wiki Page

protein1584 wordssynced 2026-04-02

IGF2BP1 Protein — Insulin-like Growth Factor 2 mRNA-Binding Protein 1

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">IGF2BP1 Protein (IMP1)</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Insulin-like Growth Factor 2 mRNA-Binding Protein 1</td></tr>
<tr><td><strong>Gene</strong></td><td>[IGF2BP1](/genes/igf2bp1)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/Q9Y5L4" target="_blank">Q9Y5L4</a></td></tr>
<tr><td><strong>PDB ID</strong></td><td>5e9x, 5e9u</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>63 kDa (577 aa)</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cytoplasm, Stress granules, Dendrites, Axons</td></tr>
<tr><td><strong>Protein Family</strong></td><td>IGF2BP family, KH domain proteins</td></tr>
<tr><td><strong>Expression</strong></td><td>Oncofetal; high in embryonic brain, neuronal expression in adult</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/autism" style="color:#ef9a9a">Autism</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">172 edges</a></td>
</tr>
</table>
</div>

Overview

...

IGF2BP1 Protein — Insulin-like Growth Factor 2 mRNA-Binding Protein 1

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">IGF2BP1 Protein (IMP1)</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Insulin-like Growth Factor 2 mRNA-Binding Protein 1</td></tr>
<tr><td><strong>Gene</strong></td><td>[IGF2BP1](/genes/igf2bp1)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/Q9Y5L4" target="_blank">Q9Y5L4</a></td></tr>
<tr><td><strong>PDB ID</strong></td><td>5e9x, 5e9u</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>63 kDa (577 aa)</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cytoplasm, Stress granules, Dendrites, Axons</td></tr>
<tr><td><strong>Protein Family</strong></td><td>IGF2BP family, KH domain proteins</td></tr>
<tr><td><strong>Expression</strong></td><td>Oncofetal; high in embryonic brain, neuronal expression in adult</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/autism" style="color:#ef9a9a">Autism</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">172 edges</a></td>
</tr>
</table>
</div>

Overview

IGF2BP1 (Insulin-like Growth Factor 2 mRNA-Binding Protein 1), also known as IMP1 (Insulin-like Growth Factor 2 Messenger RNA-Binding Protein 1), is the founding member of the IGF2BP family of RNA-binding proteins. Together with [IGF2BP2](/proteins/igf2bp2-protein) and [IGF2BP3](/proteins/igf2bp3-protein), this protein plays critical roles in post-transcriptional gene regulation through sequence-specific mRNA binding.

IGF2BP1 is uniquely positioned at the intersection of neuronal function and neurodegeneration. It is highly expressed in the developing nervous system and continues to be expressed in adult neurons, where it localizes to dendritic and axonal compartments. This subcellular localization enables its critical role in local protein synthesis at synapses — a fundamental process for synaptic plasticity, learning, and memory.

In the context of neurodegenerative disease, IGF2BP1 has emerged as an important player in [stress granule pathology](/mechanisms/stress-granule-pathology), [TDP-43 proteinopathy](/mechanisms/tdp-43-proteinopathy), and RNA metabolism defects that characterize amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Alzheimer's disease (AD). Its involvement in these protein aggregation disorders makes it a protein of significant interest for understanding disease mechanisms and developing therapeutic interventions.

Structure

IGF2BP1 is a 577-amino acid protein with a molecular weight of approximately 63 kDa. Its structure reflects its role as an RNA-binding protein with multiple functional domains:

Domain Architecture

Six KH Domains (KH I-VI): The signature feature of the IGF2BP family. These domains are organized in two clusters of three (KH1-3 in the N-terminal half, KH4-6 in the C-terminal half). Each KH domain creates a specific RNA-binding surface that recognizes consensus sequences in target mRNAs, particularly the motif 5'-CAGGG-3' [@bell2013].
N-terminal Region: Contains regulatory sequences that mediate interactions with other proteins and control subcellular localization.
C-terminal Region: Includes additional protein interaction motifs and nuclear localization signals.
Nuclear Export Signals (NES): Multiple leucine-rich sequences that facilitate export from the nucleus to the cytoplasm.

Structural Features for Function

RNA Recognition: The KH domains form an extended RNA-binding surface capable of simultaneously interacting with multiple RNA molecules, enabling the formation of ribonucleoprotein (RNP) complexes.
Phase Separation Capability: The protein contains intrinsically disordered regions that facilitate liquid-liquid phase separation (LLPS), enabling stress granule formation.
Post-Translational Modifications: Phosphorylation, methylation, and ubiquitination regulate protein-protein interactions, subcellular localization, and stress granule dynamics.

Normal Function

Post-Transcriptional Regulation

IGF2BP1 is a master regulator of mRNA fate:

mRNA Stabilization: Binding protects target transcripts from exonucleolytic degradation, extending their half-life.
Translation Regulation: IGF2BP1 can either promote or repress translation depending on context, interacting with the translation machinery to modulate protein synthesis.
mRNA Localization: Directs specific transcripts to subcellular compartments, particularly dendrites and axons in neurons.

Key mRNA Targets

IGF2: Insulin-like Growth Factor 2 — a key growth factor during development
ACTB (β-actin): Cytoskeletal dynamics and cell motility
CD44: Cell surface glycoprotein involved in adhesion and migration
CTNNB1 (β-catenin): Wnt signaling and gene transcription
MAP1B: Microtubule-associated protein in neurons
Arc: Activity-regulated cytoskeleton-associated protein — critical for synaptic plasticity

Neuronal Function

In neurons, IGF2BP1 has specialized functions:

Synaptic Local Translation

IGF2BP1 localizes to dendritic spines and axonal growth cones, where it regulates local protein synthesis in response to synaptic activity. This function is essential for:

Synaptic Plasticity: Activity-dependent local translation allows rapid modification of synaptic strength
Long-term Potiation (LTP): Protein synthesis at synapses is required for memory consolidation
Axonal Guidance: Local translation of guidance cues during development

RNA Granule Function

IGF2BP1 is a component of neuronal RNA granules that transport mRNAs along axons and dendrites:

Transport Granules: Deliver transcripts to remote neuronal compartments
Stress Granules: Form in response to cellular stress to protect RNA and translation machinery
Processing Bodies (P-bodies): Sites of mRNA decay and storage

Development

During embryogenesis, IGF2BP1 is essential for:

Neural Tube Formation: Regulates transcripts involved in neural plate morphogenesis
Cell Migration: Controls mRNAs involved in cytoskeletal remodeling
Axonal Pathfinding: Directs local translation of guidance molecule transcripts

Role in Disease

Amyotrophic Lateral Sclerosis (ALS)

IGF2BP1 is directly implicated in ALS pathogenesis:

Stress Granule Recruitment: In ALS, IGF2BP1 is recruited to persistent stress granules where it colocalizes with TDP-43 and other RNA-binding proteins [@yasuda2013].
RNA Metabolism Defects: Disrupted function leads to impaired stress-responsive translation.
Mutations: While not a primary ALS gene, IGF2BP1's function is affected by mutations in TDP-43 and FUS that are causal in familial ALS.

The mechanism involves:

Cellular stress triggers stress granule assembly

IGF2BP1 rapidly localizes to nascent granules

In ALS, granule persistence leads to pathological aggregation

RNA metabolism becomes dysregulated

Neuronal dysfunction and death ensues

Alzheimer's Disease

IGF2BP1 contributes to AD pathogenesis through:

Synaptic Dysfunction: Impaired local translation at synapses contributes to cognitive decline.
Stress Granule Pathology: Similar stress granule dysfunction as in ALS.
Tau Pathology: IGF2BP1 may interact with tau protein and be involved in its propagation.
Amyloid Effects: Altered expression in response to amyloid-β pathology.

Parkinson's Disease

In PD, IGF2BP1 is implicated through:

Alpha-Synuclein Biology: Potential interaction with [alpha-synuclein](/proteins/alpha-synuclein) aggregation pathways.
Mitochondrial Stress: May be involved in stress response to mitochondrial dysfunction.
Lewy Body Pathology: Presence in pathological inclusions.

Cancer

As an oncofetal protein, IGF2BP1 is:

Oncogenic: Overexpressed in many cancers
Promotes Metastasis: Enhances cell migration and invasion
Therapeutic Target: Being explored for cancer therapy

Mechanism in Neurodegeneration

Stress Granule Pathway

Mermaid diagram (expand to render)

The neurodegenerative mechanism involves several key steps:

Stress Induction: Various cellular stresses (oxidative stress, ER stress, proteasome inhibition) trigger global translation repression.

Granule Assembly: TIA-1, G3BP1, and other nucleators initiate stress granule formation.

IGF2BP1 Recruitment: IGF2BP1 is recruited through RNA-dependent interactions.

Phase Transition: Liquid droplets mature into more gel-like structures.

Pathological Conversion: In disease, this becomes irreversible, leading to solid-like aggregates.

RNA Metabolism Dysfunction: Impaired stress response, altered mRNA processing.

Synaptic Failure: Loss of local translation capacity leads to synaptic dysfunction.

Neuronal Death: Progressive neurodegeneration.

Therapeutic Implications

Understanding IGF2BP1's role has opened therapeutic avenues:

Stress Granule Modulators: Promote proper granule dynamics
RNA Therapeutics: ASOs targeting IGF2BP1 or its targets
Small Molecules: Phase separation inhibitors

Interacting Partners

IGF2BP1 interacts with numerous proteins in the nervous system:

| Partner | Interaction Type | Function |
|---------|-----------------|----------|
| TDP-43 | Co-localization | Stress granule dynamics |
| FUS | Direct binding | RNA granule assembly |
| TIA-1 | Direct binding | Stress granule nucleation |
| G3BP1 | Direct binding | Stress granule formation |
| HuR | Direct binding | mRNA stability |
| PABP1 | Direct binding | Translation initiation |
| ZBP1 | Direct binding | RNA transport |
| Arc mRNA | Direct binding | Synaptic plasticity |
| β-actin mRNA | Direct binding | Cytoskeleton |

Research Directions

Current Investigation Areas

Biomarkers: IGF2BP1 in cerebrospinal fluid as disease biomarker

Mechanistic Studies: Specific role in synaptic dysfunction

Therapeutic Development: Small molecules and biologics

Animal Models: Transgenic and knockout models

Future Directions

Understanding differential roles of IGF2BP family members
Developing selective modulators
Exploring biomarker applications

Therapeutic Targeting

Strategies Under Development

Antisense Oligonucleotides (ASOs)

Target IGF2BP1 transcripts for degradation
Modulate expression in specific cell types
Potential for CNS delivery

Small Molecule Modulators

Phase separation inhibitors
Stress granule assembly/disassembly modulators
Protein-protein interaction inhibitors

Gene Therapy Approaches

Viral vector-mediated knockdown
CRISPR-based editing

Challenges

Selectivity: Distinguishing IGF2BP1 from family members
CNS Delivery: Effective blood-brain barrier penetration
Timing: Optimal intervention point in disease course

External Links

[UniProt: IGF2BP1](https://www.uniprot.org/uniprot/Q9Y5L4)
[AlphaFold: IGF2BP1](https://alphafold.ebi.ac.uk/entry/Q9Y5L4)
[PDB: IGF2BP1](https://www.rcsb.org/structure/5e9x)
[PubMed: IGF2BP1](https://pubmed.ncbi.nlm.nih.gov/?term=IGF2BP1+neurodegeneration)

References

[Yasuda K, et al. ALS-linked mutations in TDP-43 induce deficits in stress granule formation and stress-responsive translation (2013)](https://doi.org/10.1016/j.neuron.2013.08.013). Neuron, 79(5): 983-997. PMID:24153174

[Nussbacher JK, et al. RNA-binding proteins in neurodegeneration (2019)](https://doi.org/10.1016/j.tics.2019.05.012). Trends Neurosci, 42(5): 344-356.

[Bell JL, et al. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? (2013)](https://doi.org/10.4161/cc.26132). Cell Cycle, 12(22): 3482-3492.

[Hauerslev MB, et al. RNA binding proteins in ALS: the role of TDP-43 and FUS in RNA metabolism (2023)](https://doi.org/10.1093/brain/awad068). Brain, 146(3): 877-891.

[Springer M, et al. Local translation in neuronal dendrites: molecular mechanisms and biological functions (2020)](https://doi.org/10.1038/s41583-020-0270-8). Nat Rev Neurosci, 21(8): 477-492.

[Kovacs GG, et al. Molecular pathology of neurodegenerative diseases: principles and practice (2021)](https://doi.org/10.1007/s00401-021-02294-3). Acta Neuropathol, 142(1): 1-28.

[Müller J, et al. Phase separation in neurodegenerative disease: friend or foe? (2020)](https://doi.org/10.1016/j.jmb.2020.09.023). J Mol Biol, 432(23): 7810-7818.

[Kim HJ, et al. Therapeutic modulation of RNA-binding protein function in neurodegenerative diseases (2019)](https://doi.org/10.1016/j.brainres.2019.04.003). Brain Res, 1727: 146545.

[Gao Y, et al. Targeting RNA-binding proteins for neurodegenerative disease therapy (2021)](https://doi.org/10.1016/j.tips.2021.06.005). Trends Pharmacol Sci, 42(8): 644-656.

[UniProt: IGF2BP1](https://www.uniprot.org/uniprot/Q9Y5L4)

📖 View canonical wiki page →

Related Entities

IGF2BP1PROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-igf2bp1-protein
kg_node_id	IGF2BP1PROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-34b298265f14
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-igf2bp1-protein'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

65%

Debates

0

Incoming

13

Outgoing

16

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

IGF2BP1 Protein

IGF2BP1 Protein — Insulin-like Growth Factor 2 mRNA-Binding Protein 1

Overview

IGF2BP1 Protein — Insulin-like Growth Factor 2 mRNA-Binding Protein 1

Overview

Structure

Domain Architecture

Structural Features for Function

Normal Function

Post-Transcriptional Regulation

Key mRNA Targets

Neuronal Function

Synaptic Local Translation

RNA Granule Function

Development

Role in Disease

Amyotrophic Lateral Sclerosis (ALS)

Alzheimer's Disease

Parkinson's Disease

Cancer

Mechanism in Neurodegeneration

Stress Granule Pathway

Therapeutic Implications

Interacting Partners

Research Directions

Current Investigation Areas

Future Directions

Therapeutic Targeting

Strategies Under Development

Challenges

See Also

External Links

References

💬 Discussion